US3100223A - Ammoniumaliphatic esters of carbamic acids - Google Patents
Ammoniumaliphatic esters of carbamic acids Download PDFInfo
- Publication number
- US3100223A US3100223A US41025A US4102560A US3100223A US 3100223 A US3100223 A US 3100223A US 41025 A US41025 A US 41025A US 4102560 A US4102560 A US 4102560A US 3100223 A US3100223 A US 3100223A
- Authority
- US
- United States
- Prior art keywords
- acid
- compound
- chloride
- butynyl
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002148 esters Chemical class 0.000 title description 5
- 150000001715 carbamic acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 23
- GRMFUFWAZRLIOC-UHFFFAOYSA-M but-2-ynyl(trimethyl)azanium;chloride Chemical compound [Cl-].CC#CC[N+](C)(C)C GRMFUFWAZRLIOC-UHFFFAOYSA-M 0.000 claims 2
- -1 alkyl radical Chemical class 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229940054025 carbamate anxiolytics Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- 241000982822 Ficus obtusifolia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- KLBOFRLEHJAXIU-UHFFFAOYSA-N tributylazanium;chloride Chemical compound Cl.CCCCN(CCCC)CCCC KLBOFRLEHJAXIU-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
Definitions
- Aryl radicals suitable as R substituents in the above general formula include the monoand di-nuclear aromatic carbocyclic aryl radicals such as phenyl, to-lyl or naphthyl.
- Substituents in these aromatic nuclei may be, for example, lower alkyl such as methyl, ethyl, propyl, butyl or pentyl; halo such as chloro, fluoro, iodo or bromo; amino, particularly tertiary amino, such as dilower alkyl amino for example, dimethyl, diethyl, or dibutylamino; or amino-lower alkoxy groups, for example dimethylaminoethoxy.
- Heterocyclic substituents on the aryl nuclei may be those containing from four to five carbon atoms, interrupted, if desired, by oxygen, nitrogen or sulfur linkages as for example, pyrrolidino, piperidino, morpholino, thiamorpholino, piperazino, etc.
- Substituents depicted by M in the above general formula may be lower alkyl radicals such as for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, etc.
- the anion Y in the above formula is more particularly a therapeutically useful anion of an acid such as that of an inorganic acid for example a hydrohalic acid, i.e., hydrochloric, hydrobromic or hydriodic acid, sulphuric acid, phosphoric acid, nitric acid or thiocyanic acid; or an organic carboxylic acid such as, for example, acetic, acetoacetic, prop-ionic, beta-cyclopentylpropionic, oxalic, malonic, succinic, maleic, fuman'c, malic, citric, tartaric, benzoic, phenylacetic, beta-phenylpropionic, salicylic acid, acetylsal-icylic, or para-aminosalicylic acid; an organic sulphonic or sulphuric acid such as, for example, paratoluenesulphonic acid, methanesulphonic acid, ethanesulphonic acid, or methyl or
- the compounds of the present invention affect the autonomic nervous system and are therefore useful in reversing tensive states. For example, certain of the compounds stimulate autonornic ganglia and thereby raise the blood pressure from a hypotensive to a normal tensive level. Others depress autonomic ganglia and are useful in loweding blood pressure from hypertensive to normal tensive levels. For this purpose they may be administered orally or intraperitoneally. The dose may be varied widely depending upon the route of administration chosen, i.e., from five to one hundred milligrams per kilogram United States Patent ice body weight intnapenitoneally, or from about two to about twenty micrograms per kilogram body weight intravenously.
- the compounds may be formulated into preparations which contain these compounds in admixture with suitable pharmaceutical organic or inorganic, solid or liquid carriers appropriate for oral or parenteral administration.
- suitable pharmaceutical organic or inorganic, solid or liquid carriers appropriate for oral or parenteral administration.
- substances which may be employed are, for example, water, gelatin, lactose, starches, magnesium stearate, talc, vegetable oils, benzyl alcohols, gums, polyalkylene glycols, cholesterol, or any other known carrier commonly used in the preparation of medicaments.
- the pharmaceutical preparations may be in the form of tablets, capsules or in liquid form such as solutions, suspensions or emulsions. If desired, they may contain auxiliary substances such as preserving agents, stabilizing agents, wetting agents, emulsifying agents, salts for varying osmotic pressure or buffers.
- novel quaternary ammonium alkyl carbamates are preparedby reacting a compound of the formula:
- novel carbamates may be prepared by reacting a compound of the formula:
- R and X substituents are as defined above and M is hydrogen or lower alkyl, with a reactive ester of an alcohol such as those with strong inorganic acids, for example hydrohalic acids, e.g., hydrochloric, hydrobromic, hydriodic or sulphuric acid; with strong onganic sulphonic acids such as, for example, aryl sulphonic acids, e.g., para-toluenesulphonic, or alky-lsulphonic acids, e.g., methanesulphonic or ethanesulphonic acid, or with strong organic sulphuric acids, for example methyl or ethyl sulphuric acid halt ester.
- preparation of the novel quaternary ammonium carbam-ates may be accomplished by reacting the appropriate 4-dialkylamino-2-alkynyl-N- (2-haloaryl) carbarnate with an alkyl halide.
- the quaternizing reactions such as outlined above are performed according to standard procedures, that is to say, in the presence or absence of a solvent at room temperature or at :an elevated temperature or under cooling at atmospheric pressure or in a closed vessel under pressure.
- Suitable solvents are, more particularly, enzene, the lower alkanols such as methanol, ethanol, prop-anol, isopropanol or amyl alcohol or organic acid amides such as formamide or dimethylformamide.
- fonmamide or dimethylformamide may be used as solvents and the reaction is advantageously run in a closed vessel under pressure.
- Introduction of the amine into the starting material may be in the form of a gas or in the form of a liquid, whichever is appropriate.
- Quaternary ammonium alkyl canbamates such as those obtained by the process of the invention may be converted into corresponding quaternary ammonium hydroxides, for example by reaction of the quaternary ammonium halides with silver oxide, or by reaction of the sulfates with barium hydroxide, or by treating the quatertherapeutically suitable quaternary ammonium salts by reaction with the acids, for example with inorganic acids such as hydrohalic acids, e.g., hydrochloric, hydrobromic or hydriodic, sulphuric, phosphoric acids, nitric acid or thiocyanic acid; or organic acids such as acetic, acetoa-cetic, propion-ic, di-lbeta-cyclopentylpropionic, oxalic, malonic, succinic, maleic, iumaric, malic, citric, tartaric, benzoic, phenylacetic, betaphenylpropionic, salicylic,
- quaternary ammonium salts obtained may also be converted into other quaternary salts directly without conversion into the quaternary hydroxide.
- a quaternary ammonion iodide maybe reacted with freshly prepared silver chloride to yield the quaternary ammonium chloride.
- Example I 12.9 parts by weight of 4-chloro-2butynyl-N-(2-chlorohenyDcarbamate is dissolved in 200 parts by volume of benzene. Trimethyl-amine gas is passed slowly into the solution for about three hours. The solid precipitate which forms is removed by filtration and recrystallized from an ethanol-ether mixture. 9.1 parts by weight of 4-'[N-(2-ehlorophenyl) carbarnoyloxy]-2-butynyl-trimethylammonium chloride is obtained. Analysis.-Ca1cu.lated for C H Cl N O Ionic Cl, 11.22. Found, 11.28.
- Example [I 20.8 parts by weight of 4-chloro-2-butenyl-N-(3-chloropheny1)carb amate, 150 parts by volume of benzene and 15.2 parts by weight of triethylamine is stirred at ambient temperature for about forty hours. The precipitate which forms is removed by filtration and dried in a desiccator over P A total of 11.5 parts by weight of 4-[N-(3- chlorophenyhcarbamoyloxy] -2 butenyl triethylammonium chloride is obtained.
- Example III A mixture of 16 parts by weight of 4-dietl1y1amino-2- butynyl-N-(Z-chlorophenyl)carbamate, 16.35 parts of ethyl bromide and 250 parts by volume of benzene is mixed and stirred at ambient temperature for forty hours. The precipitate which forms is removed by filtration and dried under reduced pressure over P 0 A total of 5.7 parts by weight of 4-[N-(Z-chlorophenyDcarbamoyloxy] -2 butynyl-trielthylammonium bromide is obtained. Analysis-Calculated for CHHMBI'CINZOZ. Ionic Br, 19.77. Found, 19.62.
- bamoyloxy -2-butynyltrimethyl ammonium chloride bamoyloxy -2-butynyltrimethyl ammonium chloride.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41025A US3100223A (en) | 1960-07-06 | 1960-07-06 | Ammoniumaliphatic esters of carbamic acids |
| FR869584A FR1330M (fr) | 1960-07-06 | 1961-07-31 | Composé d'ammonium quaternaire. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41025A US3100223A (en) | 1960-07-06 | 1960-07-06 | Ammoniumaliphatic esters of carbamic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3100223A true US3100223A (en) | 1963-08-06 |
Family
ID=21914308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US41025A Expired - Lifetime US3100223A (en) | 1960-07-06 | 1960-07-06 | Ammoniumaliphatic esters of carbamic acids |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US3100223A (fr) |
| FR (1) | FR1330M (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3621048A (en) * | 1968-03-14 | 1971-11-16 | Colgate Palmolive Co | Quaternary ammonium compounds |
| US4007281A (en) * | 1971-04-16 | 1977-02-08 | Colgate-Palmolive Company | Pharmaceutical compositions containing quaternary ammonium compounds |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1894162A (en) * | 1930-05-08 | 1933-01-10 | Dalmer Otto | New choline derivative and process for making same |
| GB734745A (en) * | 1953-10-27 | 1955-08-03 | Bofors Ab | Improvements relating to anaesthetics |
| US2772289A (en) * | 1953-03-26 | 1956-11-27 | Searle & Co | Basic esters of n-aralkyl-n-aryl-carbamic acids and the manufacture thereof |
| US2794810A (en) * | 1952-03-08 | 1957-06-04 | Searle & Co | Aminoalkyl cycloalkylcarbamates |
| US2967880A (en) * | 1957-10-21 | 1961-01-10 | Boehringer Sohn Ingelheim | Carbamic acid glycol esters |
| US2973385A (en) * | 1958-03-10 | 1961-02-28 | Searle & Co | Dialkylaminoalkyl chlorocarbanilates and process |
-
1960
- 1960-07-06 US US41025A patent/US3100223A/en not_active Expired - Lifetime
-
1961
- 1961-07-31 FR FR869584A patent/FR1330M/fr active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1894162A (en) * | 1930-05-08 | 1933-01-10 | Dalmer Otto | New choline derivative and process for making same |
| US2794810A (en) * | 1952-03-08 | 1957-06-04 | Searle & Co | Aminoalkyl cycloalkylcarbamates |
| US2772289A (en) * | 1953-03-26 | 1956-11-27 | Searle & Co | Basic esters of n-aralkyl-n-aryl-carbamic acids and the manufacture thereof |
| GB734745A (en) * | 1953-10-27 | 1955-08-03 | Bofors Ab | Improvements relating to anaesthetics |
| US2967880A (en) * | 1957-10-21 | 1961-01-10 | Boehringer Sohn Ingelheim | Carbamic acid glycol esters |
| US2973385A (en) * | 1958-03-10 | 1961-02-28 | Searle & Co | Dialkylaminoalkyl chlorocarbanilates and process |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3621048A (en) * | 1968-03-14 | 1971-11-16 | Colgate Palmolive Co | Quaternary ammonium compounds |
| US4007281A (en) * | 1971-04-16 | 1977-02-08 | Colgate-Palmolive Company | Pharmaceutical compositions containing quaternary ammonium compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| FR1330M (fr) | 1962-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68915900T2 (de) | Angiogenese hemmendes Mittel. | |
| FI66182B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-iperidinkinazolinderivat | |
| JPS6135178B2 (fr) | ||
| GB2088364A (en) | Derivatives of nortropane and granatane | |
| Holshouser et al. | Synthesis and antitumor activity of a series of sulfone analogs of 1, 4-naphthoquinone | |
| UA43834C2 (uk) | 4-аміно-1-піперидилбензоїлгуанідини, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб її одержання | |
| JPH07108881B2 (ja) | バルプロ酸または(e)―2―バルプロ酸誘導体、それらの製造法ならびにそれらを含有する抗てんかん剤または抗けいれん剤 | |
| EP0496692A1 (fr) | Dérivés de 2-méthoxyphénylpipérazine | |
| EP0144991B1 (fr) | Dérivés de polyméthoxybenzyl pipérazine, procédé pour leur préparation et compositions pharmaceutiques contenant ces dérivés | |
| US3100223A (en) | Ammoniumaliphatic esters of carbamic acids | |
| EP3705476A1 (fr) | Composé de 2-(1h-pyrazol-3-yl) phénol et son utilisation | |
| US2561385A (en) | Aranoalkyl-z-tmenyl-cycloalkenyl | |
| US3332958A (en) | Bis-(amino alkoxy phenyl)sulfides, sulfoxides and sulfones | |
| US3957789A (en) | Diaminopropanols | |
| US4139621A (en) | N-(4-substituted-3,5-dichloro-phenyl)-piperazines | |
| IL42944A (en) | Basically substituted benzene-1,3-disulfonamides and process for their manufacture | |
| US3821241A (en) | 1-imidazolyl-2-substituted hydroxy propyl amines | |
| EP1244614A2 (fr) | Inhibiteurs de tryptase | |
| US2991283A (en) | Substituted amino alkyl esters of paraalkyl sulfamide benzoic acids | |
| US4042590A (en) | Diaminopropanols | |
| DE68906427T2 (de) | Propan-Derivate. | |
| US3133067A (en) | 1-monocarbocyclic aryl-4-thiocarbam-ylpiperazines and intermediates and processes therefor | |
| Halverstadt et al. | Hypotensors. 2-Ammonioalkyl 3-Ammonioalkanoate Salts1 | |
| US3322768A (en) | Aralkyl piperazines and salts thereof | |
| US3758527A (en) | Esters of 1-aminoalkyl-cycloalkanols |